Aclaris Therapeutics (ACRS) Total Debt (2017 - 2022)
Aclaris Therapeutics (ACRS) posted quarterly Total Debt of $2.7 million for Q3 2022, down 12.2% year-over-year from $3.1 million in Q3 2021, and little changed quarter-over-quarter from $2.7 million in Q2 2022.
Aclaris Therapeutics (ACRS) Total Debt (2017 - 2022) Analysis & Trends
Aclaris Therapeutics' Total Debt history runs 6 years deep, the most recent figure standing at $2.7 million for Q3 2022.
- In Q3 2022, Total Debt fell 12.2% year-over-year to $2.7 million; the TTM figure through Sep 2022 stood at $2.7 million (down 12.2% YoY), while the FY2021 annual figure was $2.6 million, down 75.12% from the prior year.
- Total Debt for Q3 2022 stood at $2.7 million, roughly flat from $2.7 million in the prior quarter.
- The five-year high for Total Debt was $29.9 million in Q3 2019, with the low at $2.6 million in Q4 2021.
- The 5-year median for Total Debt is $10.6 million (2020), against an average of $13.4 million.
- The sharpest annual moves came in 2018 and 2022: Total Debt jumped 4970.17% in 2018, then tumbled 80.44% in 2022.
- Aclaris Therapeutics' Total Debt stood at $29.9 million in 2018, then grew by 0.05% to $29.9 million in 2019, then plunged by 64.41% to $10.7 million in 2020, then tumbled by 75.12% to $2.6 million in 2021, then climbed by 1.89% to $2.7 million in 2022.
- Business Quant data shows ACRS's Total Debt at $2.7 million in Q3 2022, $2.7 million in Q2 2022, and $2.7 million in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.07 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.34 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 2.70 Mn |
| Jun 30, 2022 | 2.70 Mn |
| Mar 31, 2022 | 2.70 Mn |
| Dec 31, 2021 | 2.65 Mn |
| Sep 30, 2021 | 3.08 Mn |
| Jun 30, 2021 | 13.81 Mn |
| Mar 31, 2021 | 10.69 Mn |
| Dec 31, 2020 | 10.65 Mn |
| Sep 30, 2020 | 10.61 Mn |
| Jun 30, 2020 | 10.57 Mn |
| Mar 31, 2020 | 10.57 Mn |
| Sep 30, 2019 | 29.93 Mn |
| Jun 30, 2019 | 29.92 Mn |
| Mar 31, 2019 | 29.92 Mn |
| Dec 31, 2018 | 29.91 Mn |
| Dec 31, 2017 | 590,000.00 |